Cancer Diagnostics Market to Hit $41.5B by 2031, Driven by Precision Oncology and AI
Event summary
- The global cancer diagnostics market is projected to grow from $29.3B in 2026 to $41.5B by 2031, at a CAGR of 7.2%.
- Precision oncology and AI-driven diagnostics are key growth drivers, with molecular testing and liquid biopsy gaining traction.
- Recent strategic moves include Roche's $1.05B acquisition of PathAI and Danaher's acquisition of StatLab Medical Products.
- North America leads the market, while Asia Pacific is the fastest-growing region due to expanding healthcare infrastructure.
The big picture
The cancer diagnostics market is evolving beyond traditional imaging and pathology, with precision oncology and AI-driven tools becoming central to diagnosis and treatment. Strategic acquisitions and partnerships, such as Roche's acquisition of PathAI and Siemens Healthineers' collaboration with Vanderbilt Health, reflect the industry's focus on integrating advanced technologies into diagnostic workflows. The market's growth is fueled by increasing cancer prevalence, earlier detection efforts, and the need for personalized treatment approaches.
What we're watching
- Precision Oncology
- How the integration of molecular and genomic testing will shape the future of cancer diagnostics and treatment.
- AI Adoption
- The pace at which AI tools for imaging, digital pathology, and lesion detection will gain clinical validation and regulatory approval.
- Regional Expansion
- Whether Asia Pacific can sustain its rapid growth as healthcare infrastructure and public screening programs expand.
Related topics
